胰腺癌术前隐匿性肝转移的外泌体特征模型
这项多中心回顾性病例对照研究纳入372例胰腺导管腺癌患者,开发并外部验证了基于循环外泌体miRNA的机器学习模型,用于术前检测隐匿性早期肝转移。7-exo-miRNA极端梯度提升模型在训练队列和两个外部验证队列中均表现出良好区分度, panel评分是多变量分析中早期肝转移的独立识别因素。
要点
- 7-exo-miRNA极端梯度提升模型可用于术前识别胰腺癌隐匿性早期肝转移风险。
- 早期肝转移患者中位总生存期9.1个月,显著差于其他复发模式。
- 外泌体panel评分是多变量分析中早期肝转移的独立识别因素。
核心结论
- 基于循环外泌体miRNA的机器学习模型可在术前检测胰腺导管腺癌隐匿性早期肝转移风险。
研究设计与样本
- 多中心回顾性病例对照研究,纳入中国、日本和韩国4个医学中心2011至2024年的372例胰腺导管腺癌患者。
- 研究分三阶段:全基因组发现(外泌体miRNA测序)、模型开发(训练队列)和独立外部验证(2个验证队列)。
- 主要结局为早期肝转移,定义为根治性切除术后6个月内肝复发。
主要发现
- 372例患者中位年龄67岁(IQR 59-73),男性229例(61.6%),女性143例(38.4%),生存者中位随访969天。
- 早期肝转移与其他复发模式相比总生存期显著更差(中位OS 9.1个月 vs 26.6-31.8个月;log-rank P < .001)。
- 7-exo-miRNA极端梯度提升模型在训练队列AUC为0.899(95% CI 0.822-0.976),外部测试队列AUC分别为0.876(95% CI 0.846-0.951)和0.862(95% CI 0.744-0.981)。
- 多变量分析中exo-miRNA panel评分是早期肝转移的独立识别因素(OR 26.49;95% CI 18.45-55.28;P < .001),并可分层总生存期(log-rank P < .001)。
- 决策曲线分析提示较传统临床病理变量有更好的净临床获益。
临床怎么用
- 该模型有望用于胰腺癌术前风险评估,辅助识别隐匿性早期肝转移高危患者。
- 研究结果支持外泌体生物标志物用于生物学指导的治疗排序,但需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Early liver metastasis (early-LiM) after pancreatectomy represents an aggressive biological phenotype of pancreatic ductal adenocarcinoma (PDAC) and is associated with markedly poor survival. Reliable preoperative biomarkers to identify occult hepatic micrometastasis remain lacking. OBJECTIVE: To develop and externally validate a circulating exosomal microRNA (exo-miRNA)-based machine learning model for preoperative detection of occult early-LiM in PDAC. DESIGN, SETTING, AND PARTICIPANTS: This multicenter retrospective case-control study included 3 phases: genome-wide discovery using exo-miRNA sequencing (discovery cohort), model development (training cohort), and independent external validation (2 validation cohorts). The study took place at 4 medical centers in China, Japan, and South Korea. A total of 372 patients were enrolled between 2011 and 2024. Data were analyzed from July 2024 to November 2025. EXPOSURES: Circulating plasma-derived exosomal miRNA expression profiles. MAIN OUTCOMES AND MEASURES: The primary outcome was early-LiM, defined as liver recurrence within 6 months after curative-intent resection. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC) and survival outcomes were assessed using Kaplan-Meier analysis. RESULTS: Among 372 patients with PDAC (median [IQR] age, 67 [59-73] years; 229 [61.6%] male and 143 [38.4%] female; median follow-up among survivors, 969 days),early-LiM was associated with significantly worse overall survival compared with other recurrence patterns (median OS, 9.1 months vs 26.6-31.8 months; log-rank P < .001). A 7-exo-miRNA extreme gradient boosting model demonstrated discrimination in the training cohort (AUC, 0.899; 95% CI, 0.822-0.976) and maintained performance in external testing cohorts (AUC, 0.876; 95% CI, 0.846-0.951 and AUC, 0.862; 95% CI, 0.744-0.981). The exo-miRNA panel score remained an independent identifier of early-LiM in multivariable analysis (odds ratio, 26.49; 95% CI, 18.45-55.28; P < .001) and stratified overall survival (log-rank P < .001). Decision curve analysis suggested improved net clinical benefit compared with conventional clinicopathologic variables. CONCLUSION AND RELEVANCE: In this multicenter study, a circulating exo-miRNA-based machine learning model enabled preoperative detection of occult early liver metastasis risk in PDAC. These findings support the potential of exosomal biomarkers to inform biology-guided treatment sequencing and warrant prospective validation.
引用
- Noma T, Yin J, Zhang J, et al. An Exosomal Signature for Preoperative Detection of Occult Liver Metastasis in Pancreatic Cancer. JAMA Surg. 2026. PMID: 42684725. doi:10.1001/jamasurg.2026.3840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。